Smith & Nephew plc: Q2 and H1 2025 Results Summary
Business Context and Reporting Period
This Form 6-K filing reports the Second Quarter and First Half 2025 results for Smith & Nephew plc, a global medical technology company. The reporting period covers the six months ended June 28, 2025. The company operates three primary business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The results reflect the ongoing execution of the "12-Point Plan" transformation strategy.
Key Financial Metrics (H1 2025)
| Metric | H1 2025 ($m) | H1 2024 ($m) | Change (%) |
|---|---|---|---|
| Revenue | 2,961 | 2,827 | 4.7% (Reported) / 5.0% (Underlying) |
| Operating Profit | 429 | 328 | 30.6% |
| Trading Profit | 523 | 471 | 11.2% |
| Trading Profit Margin | 17.7% | 16.7% | +100 bps |
| EPS (Basic) | 33.5 cents | 24.5 cents | 36.6% |
| EPSA (Adjusted) | 42.9 cents | 37.6 cents | 14.1% |
| Cash from Operations | 568 | 368 | 54.3% |
| Free Cash Flow | 244 | 39 | 528.3% |
| Net Debt | 2,747 | 2,709 | Stable |
Material Changes vs. Prior Period
- Revenue Growth Acceleration: Q2 underlying revenue growth accelerated to 6.7% (reported 7.8%), driven by a 110bps FX tailwind. All regions and business units grew ahead of Q1.
- Margin Expansion: Trading profit margin expanded by 100 basis points to 17.7%, driven by revenue leverage and operational savings. Orthopaedics margin increased by 230bps, while Sports Medicine & ENT declined 130bps due to China Volume Based Procurement (VBP) headwinds.
- Cash Flow Improvement: Trading cash conversion improved significantly by 33 percentage points to 93%, primarily due to favorable working capital movements. Day Sales of Inventory (DSI) decreased by 46 days year-over-year.
- Restructuring Costs: Restructuring charges dropped significantly to $8 million in H1 2025 compared to $62 million in H1 2024 as the 12-Point Plan nears completion.
Guidance, Outlook, and Management Commentary
- Full Year Guidance Unchanged: Management expects underlying revenue growth of around 5.0% (reported ~5.5%) and a full-year trading profit margin expansion to between 19.0% and 20.0%.
- Shareholder Returns: Announced an additional $500 million share buyback to be executed in the second half of 2025. The interim dividend was increased by 4.2% to 15.0 cents per share.
- Tariff Impact: The outlook includes an expected net impact of $15 to $20 million from tariffs in 2025, based on announced measures and mitigations.
- CEO Commentary: CEO Deepak Nath highlighted sustained higher revenue growth, increased profitability, and better cash generation. He noted that new products launched in the last five years accounted for three-quarters of H1 growth.
- Risks: Key risks include China VBP implementation, potential headwinds from proposed Medicare reimbursement updates for skin substitutes in 2026, and geopolitical/tariff uncertainties.
Investor Verification Checklist
- China VBP Impact: Verify the extent of revenue and margin pressure in the Sports Medicine & ENT segment due to Volume Based Procurement in China.
- Inventory Reduction Sustainability: Confirm if the 46-day reduction in DSI is sustainable or a one-time working capital release.
- Medicare Reimbursement: Monitor the finalization of proposed Medicare updates for skin substitutes and their potential impact on 2026 Advanced Wound Management profitability.
- Tariff Mitigation: Assess the effectiveness of the company's mitigation strategies regarding the projected $15-$20 million tariff impact.
- Buyback Execution: Track the execution of the announced $500 million share buyback in H2 2025.